Mihaela Aldea, Julia K Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl, Christian Rolfo, Marco Tagliamento, Teodora Radonic, Kurt A Schalper, Vivek Subbiah, Umberto Malapelle, Anja C Roden, Rami Manochakian, Ming-Sound Tsao, Helena Linardou, Rina Hui, Silvia Novello, Alastair Greystoke, Anjali Saqi, Sylvie Lantuejoul, David M Hwang, Kelly Nevins, Murry Wynes, Saiama Waqar, Yuchen Han, Yasushi Yatabe, Wei-Chin Chang, Takuo Hayashi, Tae-Jung Kim, Paul Hofman, Fabio Tavora, Fred R Hirsch, Valeria Denninghoff, Natasha B Leighl, Alexander Drilon, Wendy A Cooper, Sanja Dacic, Pranshu Mohindra, Nick Pavlakis, Fernando Lopez-Rios
{"title":"分子肿瘤委员会：国际肺癌研究协会的共识声明。","authors":"Mihaela Aldea, Julia K Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl, Christian Rolfo, Marco Tagliamento, Teodora Radonic, Kurt A Schalper, Vivek Subbiah, Umberto Malapelle, Anja C Roden, Rami Manochakian, Ming-Sound Tsao, Helena Linardou, Rina Hui, Silvia Novello, Alastair Greystoke, Anjali Saqi, Sylvie Lantuejoul, David M Hwang, Kelly Nevins, Murry Wynes, Saiama Waqar, Yuchen Han, Yasushi Yatabe, Wei-Chin Chang, Takuo Hayashi, Tae-Jung Kim, Paul Hofman, Fabio Tavora, Fred R Hirsch, Valeria Denninghoff, Natasha B Leighl, Alexander Drilon, Wendy A Cooper, Sanja Dacic, Pranshu Mohindra, Nick Pavlakis, Fernando Lopez-Rios","doi":"10.1016/j.jtho.2025.07.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Molecular Tumor Boards (MTBs) are multidisciplinary meetings of specialists dedicated to analyzing biomarker test results to provide personalized treatment recommendations. However, global disparities in the successful implementation of MTBs exist, driven by unequal access to molecular diagnostics and supportive multidimensional expertise.</p><p><strong>Objective: </strong>To establish recommendations for MTB implementation, outline practical frameworks for their operation, and address disparities in expertise and resources between new and established MTBs.</p><p><strong>Design: </strong>A modified Delphi method involved 37 international experts in three survey rounds and online meetings, with consensus defined as ≥75% agreement.</p><p><strong>Results: </strong>The panel identified a molecular biologist or pathologist with expertise in molecular diagnostics and tumor-specific medical oncologists as indispensable MTB members. Case selection should reflect institutional expertise and volume, with newer MTBs reviewing less selected cases to gain experience. Regular meetings are advised to avoid delays beyond 14 days from result availability to discussion. Reporting should be standardized to include clinicopathologic data (tumor characteristics, treatment history), biomarker findings (testing results, sample details), and recommendations (treatment, retesting, genetic counseling). Treatment options should be ranked by the level of evidence for actionability and may include options not available locally. Performance evaluation should consider changes in patient management based on MTB input and matched therapy rates.</p><p><strong>Conclusions: </strong>These MTB consensus recommendations are applicable across tumor types, despite being developed by lung cancer and molecular specialists and initiated by the International Association for the Study of Lung Cancer (IASLC). They provide a structured framework for MTB implementation, report standardization, case selection, and quality assessment, aiming to standardize practice and address gaps in expertise for personalized cancer care.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer.\",\"authors\":\"Mihaela Aldea, Julia K Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl, Christian Rolfo, Marco Tagliamento, Teodora Radonic, Kurt A Schalper, Vivek Subbiah, Umberto Malapelle, Anja C Roden, Rami Manochakian, Ming-Sound Tsao, Helena Linardou, Rina Hui, Silvia Novello, Alastair Greystoke, Anjali Saqi, Sylvie Lantuejoul, David M Hwang, Kelly Nevins, Murry Wynes, Saiama Waqar, Yuchen Han, Yasushi Yatabe, Wei-Chin Chang, Takuo Hayashi, Tae-Jung Kim, Paul Hofman, Fabio Tavora, Fred R Hirsch, Valeria Denninghoff, Natasha B Leighl, Alexander Drilon, Wendy A Cooper, Sanja Dacic, Pranshu Mohindra, Nick Pavlakis, Fernando Lopez-Rios\",\"doi\":\"10.1016/j.jtho.2025.07.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context: </strong>Molecular Tumor Boards (MTBs) are multidisciplinary meetings of specialists dedicated to analyzing biomarker test results to provide personalized treatment recommendations. However, global disparities in the successful implementation of MTBs exist, driven by unequal access to molecular diagnostics and supportive multidimensional expertise.</p><p><strong>Objective: </strong>To establish recommendations for MTB implementation, outline practical frameworks for their operation, and address disparities in expertise and resources between new and established MTBs.</p><p><strong>Design: </strong>A modified Delphi method involved 37 international experts in three survey rounds and online meetings, with consensus defined as ≥75% agreement.</p><p><strong>Results: </strong>The panel identified a molecular biologist or pathologist with expertise in molecular diagnostics and tumor-specific medical oncologists as indispensable MTB members. Case selection should reflect institutional expertise and volume, with newer MTBs reviewing less selected cases to gain experience. Regular meetings are advised to avoid delays beyond 14 days from result availability to discussion. Reporting should be standardized to include clinicopathologic data (tumor characteristics, treatment history), biomarker findings (testing results, sample details), and recommendations (treatment, retesting, genetic counseling). Treatment options should be ranked by the level of evidence for actionability and may include options not available locally. Performance evaluation should consider changes in patient management based on MTB input and matched therapy rates.</p><p><strong>Conclusions: </strong>These MTB consensus recommendations are applicable across tumor types, despite being developed by lung cancer and molecular specialists and initiated by the International Association for the Study of Lung Cancer (IASLC). They provide a structured framework for MTB implementation, report standardization, case selection, and quality assessment, aiming to standardize practice and address gaps in expertise for personalized cancer care.</p>\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jtho.2025.07.009\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtho.2025.07.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer.
Context: Molecular Tumor Boards (MTBs) are multidisciplinary meetings of specialists dedicated to analyzing biomarker test results to provide personalized treatment recommendations. However, global disparities in the successful implementation of MTBs exist, driven by unequal access to molecular diagnostics and supportive multidimensional expertise.
Objective: To establish recommendations for MTB implementation, outline practical frameworks for their operation, and address disparities in expertise and resources between new and established MTBs.
Design: A modified Delphi method involved 37 international experts in three survey rounds and online meetings, with consensus defined as ≥75% agreement.
Results: The panel identified a molecular biologist or pathologist with expertise in molecular diagnostics and tumor-specific medical oncologists as indispensable MTB members. Case selection should reflect institutional expertise and volume, with newer MTBs reviewing less selected cases to gain experience. Regular meetings are advised to avoid delays beyond 14 days from result availability to discussion. Reporting should be standardized to include clinicopathologic data (tumor characteristics, treatment history), biomarker findings (testing results, sample details), and recommendations (treatment, retesting, genetic counseling). Treatment options should be ranked by the level of evidence for actionability and may include options not available locally. Performance evaluation should consider changes in patient management based on MTB input and matched therapy rates.
Conclusions: These MTB consensus recommendations are applicable across tumor types, despite being developed by lung cancer and molecular specialists and initiated by the International Association for the Study of Lung Cancer (IASLC). They provide a structured framework for MTB implementation, report standardization, case selection, and quality assessment, aiming to standardize practice and address gaps in expertise for personalized cancer care.
期刊介绍：
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
